Class / Patent application number | Description | Number of patent applications / Date published |
514626000 | Nitrogen in R | 78 |
20080207762 | METHOD OF TREATING INFLAMMATORY ACNE VULGARIS WITH CARBAMIDE PEROXIDE - A method of treating inflammatory acne vulgaris comprises the topical application of a formulation incorporating carbamide peroxide in a pharmaceutically acceptable vehicle. Inflammatory acneform lesions that can be successfully treated with the inventive method include erythematous papules, pustules, nodules, and cysts. Suitable pharmaceutical vehicles for the topical application of carbamide peroxide include creams, gels, lotions, solutions, suspensions, and ointments. | 08-28-2008 |
20080242731 | TOPICAL ANESTHESIA FORMULATION FOR BODILY CAVITIES - The present invention relates to topical anaesthetic compositions, uses thereof and methods for their preparation. | 10-02-2008 |
20080249181 | Compositions Having Antimycrobial Activity Including a Hydroxamate or a Hydroxamate and a Hydroxlyamine - Antimycorbacterial compositions are disclosed comprising at least one hydroxamate or at least one hydroxamate and at least one hydroxylamine. The preferred ratio of hydroxamate to hydroxylamines is about 100:1 to about 1:1. A method for inhibiting mycobacterial growth is also disclosed comprising the step of administering the compositions of this invention to an animal including a human. | 10-09-2008 |
20080249182 | Crystalline Modification of N-Ethyl-2,2-Dichloro-1-Methylcyclopropane-Carboxamide-2-(2,6-Dichloro-Alpha, Alpha, Alpha-Trifluoro-P-Tolyl)Hydrazone - The present invention relates to a novel crystalline modification of N-ethyl-2,2-dichloro-1-methylcyclopropane-carboxamide-2-(2,6-dichloro-α,α,α-trifluoro-p-tolyl)hydrazone, to a process for its preparation and to its use for combating pests and parasites. Further, the invention relates to pesticidal and parasiticidal mixtures and compositions comprising said crystalline modification. | 10-09-2008 |
20080312331 | Method of Treating Dailysis-Induced Hypotension - A method is described for the treatment of hypotension, e.g., intra-dialytic hypotension, which is based on the administration to a patient, e.g. a dialysis patient during dialysis, of midodrine or a midodrine metabolite which will increase a lowered blood pressure in the patient or relieve a symptom caused by the dialysis procedure. | 12-18-2008 |
20090036539 | STABLE HYPERBARIC COMPOSITION COMPRISING PRILOCAINE HCL, USE OF SAID NEW COMPOSITION FOR INTRATHECAL ANAETHESIA, AND METHOD FOR MANUFACTURING SAID COMPOSITION - The present invention concerns new preservative-free hyperbaric compositions of prilocaine HCI intended for use in intrathecal narcosis, characterized by high stability at ambient temperature (15° C.-27° C.). The present invention also concerns a method for manufacturing said compositions. | 02-05-2009 |
20090048347 | Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic - The invention relates to a drug delivery system for the topical administration of anesthetic agents. For example, a topical anesthetic for rapid local anesthesia is provided. The topical anesthetic includes an anesthetic, volatile and non-volatile solvents, and an optional thickener. In addition, a method is taught for applying the topical anesthetic to the face of a patient without occlusion. The anesthetic is applied topically to an area for injection such that the dermatological procedure (cosmetic injections) can be performed in fifteen minutes. | 02-19-2009 |
20090082465 | DEUTERIUM-ENRICHED LISDEXAMFETAMINE - The present application describes deuterium-enriched lisdexamfetamine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-26-2009 |
20090093547 | Compositions and Methods for Treating Premature Ejaculation - Compositions and methods for the treatment of premature ejaculation have been developed. It has been discovered that premature ejaculation can be treated by administering a local anesthetic to the glans penis. The local anesthetic may be formulated as an emulsion, lotion, paste, gel, cream, ointment, shea butter, suspension, solution, balm, salve, foam, or in the form of a pump spray to achieve local anesthesia of the dorsal neurons of the penis. | 04-09-2009 |
20090163597 | Preparation for Iontophoresis - A preparation used for iontophoresis in order to absorb a physiologically active substance via the skin or mucosa using electrical driving force and the preparation containing a local anesthetic, epinephrine or its salt, water and chlorobutanol. | 06-25-2009 |
20090170953 | INDENTIFICATION OF COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS - The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compounds that inhibit HIV, methods to isolate and synthesize modified glycinamide compounds, and therapeutic compositions comprising these compounds. | 07-02-2009 |
20090203794 | Aqueous Anaesthetic Composition Comprising Propofol - The invention discloses an aqueous anaesthetic Propofol composition that is stable, autoclave sterilized, suitable for parental administration, having reduced incidence of pain upon injection. The composition comprises propofol, 2-hydroxypropyl-β-cyclodextrin and a local anaesthetic, Lignocaine. | 08-13-2009 |
20100016441 | BIOCIDAL COMPOSITION AND METHOD - Composition and method for the inhibition of microbial growth in alkaline aqueous media requiring both rapid decontamination and long term preservation. The composition is a blend of 2,2-dibromo-3-nitrilopropionamide and 2-bromo-2-nitro-1,3-propanediol. | 01-21-2010 |
20100016442 | SMALL MOLECULE SOLUBILIZATION SYSTEM - The invention relates to a drug delivery system for the topical administration of therapeutic agents. | 01-21-2010 |
20100041765 | HIGH CONCENTRATION LOCAL ANESTHETIC FORMULATIONS - A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours. | 02-18-2010 |
20100048722 | FORMATION OF ACCUMBENS GluR2-LACKING AMPA RECEPTORS MEDIATES INCUBATION OF COCAINE CRAVING - The present invention provides a method for ameliorating cue-induced cravings for an addictive substance in abstinent addicts by administering a compound capable of blockade of GluR2-lacking AMPA receptors. | 02-25-2010 |
20100069500 | AMIDE DENDRIMER COMPOSITIONS - Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester. | 03-18-2010 |
20100099772 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS - The invention features a method for inhibiting one or more voltage-gated ion channels in a cell by contacting the cell with (i) a first compound that activates a channel-forming receptor that is present on nociceptors and/or pruriceptors; and (ii) a second compound that inhibits one or more voltage-gated ion channels when applied to the internal face of the channels but does not substantially inhibit said channels when applied to the external face of the channels, wherein the second compound is capable of entering nociceptors or pruriceptors through the channel-forming receptor when the receptor is activated. The invention also features a quarternary amine derivative or other permanently or transiently charged derivative of a compound that inhibits one or more voltage-gated ion channels when applied to the internal face of the channels but does not substantially inhibit said channels when applied to the external face of the channels. | 04-22-2010 |
20100234470 | Instillation Administration of Capsaicinoids for the Treatment of Pain - This present invention relates to methods for treating or attenuating pain in a patient. Specifically, the invention provides a method for attenuating pain in proximity to the site of an open wound or surgical incision comprising instilling a pharmaceutical composition comprising a capsaicinoid into the wound or incision, allowing the pharmaceutical composition to dwell for a predetermined period of time, and aspirating the wound or incision to remove the pharmaceutical composition. The invention also provides a method for attenuating pain in proximity to a joint comprising intra-articularly injecting a pharmaceutical composition comprising a capsaicinoid into the joint, allowing the pharmaceutical composition to dwell for predetermined period of time, and aspirating the joint to remove the pharmaceutical composition. In certain embodiments of the invention, the capsaicinoid is capsaicin. | 09-16-2010 |
20100234471 | LIDOCAINE TAPE PREPARATION - The present invention discloses a novel tape preparation containing lidocaine at a high concentration. A tape preparation containing lidocaine at a high content, which has a lidocaine contant of 10 w/w % or more, can be produced by using a lactic acid salt of lidocaine, while preventing the precipitation of a crystal of lidocaine. | 09-16-2010 |
20100249240 | SYNERGISTIC MIXED POLOXAMER SYSTEMS FOR THE SOLUBILISATION OF DRUGS - Drugs which are difficult to solubilise in water, and especially those which otherwise cause pain on injection, can be readily formulated and typically administered with substantially less pain when solubilised in synergistic, aqueous micellar preparations of poloxamers. Such preparations may also be prepared with less, or without, co-solvents. | 09-30-2010 |
20110039937 | NOVEL PROCESS FOR THE PREPARATION OF VORINOSTAT - The present invention relates to an improved process for the preparation of the active pharmaceutical ingredient, vorinostat. In particular it relates to an efficient process for the preparation of vorinostat of high purity without the requirement to isolate any synthetic intermediate compounds. | 02-17-2011 |
20110054035 | Combination Comprising Combretastatin and Anticancer Agents - This invention relates to therapeutic combinations comprising VEGF Trap and a stilbene derivative, and to methods for treatment of cancer comprising administration of such combinations. | 03-03-2011 |
20110086922 | SENSORY-SPECIFIC LOCAL ANESTHESIA AND PROLONGED DURATION LOCAL ANESTHESIA - Combinations of charged local anesthetics with chemical permeation enhancers have been developed to give long duration block which is selective for sensory block over motor block. The duration of block is greatly prolonged by combining the local anesthetic with a permeation enhancer. The selectivity of sensory over motor block is provided by selecting the concentration of the local anesthetic and the permeation enhancer to provide selective permeability of the sensory and motor neurons to the enhancer. | 04-14-2011 |
20110152377 | EXTERNAL PREPARATION COMPRISING FATTY ACID SALT OR BENZOIC ACID SALT OF BASIC PHARMACOLOGICALLY ACTIVE COMPONENT, AND METHOD FOR PRODUCTION THEREOF - It has been demanded to develop a formulation for a novel external preparation having excellent transdermal absorption of a basic pharmacologically active component contained therein. It is found that the lipid solubility (logP values) of a basic pharmacologically active component and an organic acid (particularly a fatty acid) contribute significantly to the transdermal absorption of the basic pharmacologically active component in the selection of proper combinations of the basic pharmacologically active component and the organic acid. Namely, it is found that superior transdermal absorption of a basic pharmacologically active component having a lipid solubility level of 0.5 to 5 can be achieved by forming a salt of the component with a fatty acid having a lipid solubility level of −1 to 4. Thus, it becomes possible to provide a novel external preparation having excellent transdermal absorption properties. | 06-23-2011 |
20110184068 | USE OF (HALOBENZYLOXY) BENZYLAMINO-PROPANAMIDES FOR THE MANUFACTURE OF MEDICAMENTS ACTIVE AS SODIUM AND/OR CALCIUM CHANNEL SELECTIVE MODULATORS - The invention relates to the use of selected (R)-2-[(halobenzyloxy)benzylamino]-propanamides and the pharmaceutically acceptable salts thereof for the manufacture of medicament, that are selectively active as sodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, pain, migraine, periferal diseases, cardiovascular diseases, inflammatory processes affecting all body systems, disorders affecting skin and related tissues, disorders of the respiratory system, disorders of the immune and endocrinological systems, gastrointestinal, urogenital, metabolic and seizure disorders, where the above mechanisms have been described as playing a pathological role. | 07-28-2011 |
20110224305 | PHENYLCYCLOBUTYLAMIDE DERIVATIVES AND THEIR STEREOISOMERS, THE PREPARATION PROCESSES AND USES THEREOF - Phenylcyclobutylamide derivatives and their optical isomers, the preparing processes and the uses thereof, which includes the compounds of formula (I), their pure stereoisomers and their pharmaceutically acceptable salts. In formula (I), R is H, formacyl, acetyl, haloacetyl, benzoyl, benzyloxy carbonyl (Cbz), t-butoxy carbonyl (Boc), or 9-fluorenyl methoxyl carbonyl (Fmoc). The present novel compounds have pharmaceutical activity and are prepared by condensation reaction of racemic, levo- or dextro-demethyl Sibutramine and racemic or D/L isoleucine under a mild condition. It is demonstrated that the present compounds have effect of losing weight to obese mode rats in different level and the effect is better than Sibutramine by the animal experiments. So the medicaments prepared by the present compounds or the medicaments prepared by the compositions of the present compounds and other pharmaceutical activity compounds may be used for treating obesity. | 09-15-2011 |
20110263715 | Local Anesthetic Emulsion Compositions and Methods of Making and Using the Same - Local anesthetic emulsion compositions are provided. The local anesthetic emulsion compositions may include: an oily phase comprising a eutectic mixture of a local anesthetic and an acyclic amide; a surfactant; and an aqueous phase. Also provided are methods of making and using the emulsions. | 10-27-2011 |
20110294894 | Pharmaceutical Composition for the Treatment of Solar Urticaria - The present invention refers to a local anesthetic, preferably selected from the group of aminoamide local anesthetics, in particular lidocaine or prilocaine, for use in the treatment or prevention of physical urticaria, in particular solar urticaria. The present invention further refers to a pharmaceutical composition, e.g. a cream, comprising such a local anesthetic, in particular a combination of lidocaine and prilocaine. | 12-01-2011 |
20120029085 | STABILIZATION OF QUINOL COMPOSITION SUCH AS CATECHOLAMINE DRUGS - Compositions and methods are provided for obtaining stabilized quinol compositions, such as catecholamine drugs (e.g., epinephrine solutions), and also for obtaining stable pharmaceutical formulations that comprise a stabilized quinol composition and a second pharmacologically active component such as a local anesthetic or other active drug ingredient having a reversibly protonated amine group. Stability is achieved through the inclusion of an appropriately selected pH buffer and a thiol agent, based on redox and pH buffering principles including pKa of the buffer and of the reversibly protonated amine group. | 02-02-2012 |
20120095104 | USE OF VASOCONSTRICTORS - There is disclosed the topical dermal use of vasocontrictor substances for regulating body temperature to treat, prevent or delay the onset of anesthetic induced hypothermia. Kits containing appropriate materials and instructions, and other embodiments, are also disclosed. | 04-19-2012 |
20120149779 | HIGH CONCENTRATION LOCAL ANESTHETIC FORMULATIONS - A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours. | 06-14-2012 |
20120208890 | STABLE HYDROGEL COMPOSITIONS INCLUDING ADDITIVES - The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions. | 08-16-2012 |
20120214874 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE - In one embodiment, the present invention provides a topical composition including a topically acting anesthetic active ingredient; an ester; a non-ionic surfactant; a polar solvent; water, and optionally a buffer, a pH adjusting agent or an anti-oxidant. The compositions are useful for alleviating pain especially associated with acute herpes zoster. | 08-23-2012 |
20130041038 | HYALURONIC ACID-BASED GELS INCLUDING LIDOCAINE - Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided. | 02-14-2013 |
20130041039 | HYALURONIC ACID-BASED GELS INCLUDING LIDOCAINE - Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided. | 02-14-2013 |
20130046025 | COMPOSITION WITH LOW SKIN IRRITATION FOR TRANSDERMAL DELIVERY OF TOLTERODINE - Disclosed is a composition for transdermal administration containing tolterodine. The composition comprises at least one essential oil as an abirritant to minimize skin irritation caused by tolterodine. The composition relieves skin irritation caused by tolterodine. Therefore, a successful commercial application of a tolterodine-containing transdermal preparation based on the composition can be expected. | 02-21-2013 |
20130053447 | DESENSITIZING DRUG PRODUCT - Desensitizing drug products, methods of making desensitizing drug products, and methods of using desensitizing drug products including delivery of desensitizing drug products. In one embodiment, the desensitizing drug products are male genital desensitizers that comprise one or anesthetic agents and one or more melting point depressing agents. | 02-28-2013 |
20130079415 | COMPOSITIONS COMPRISING AMPHETAMIN AND LISDEXAMFETAMINE - A formulation comprising dexamphetamine and lys-dexamphetamine useful in the treatment of ADHD or fatigue. | 03-28-2013 |
20130116328 | Thermogelling Anaesthetic Compositions - The present invention relates to a thermogelling pharmaceutical composition comprising local anaesthetics in base form and which is suitable for topical administration. The compositions further comprise a polyoxyethylene castor oil and one or more surfactants to obtain thermogelling characteristics. | 05-09-2013 |
20130116329 | Treatment for Reducing Inflammation - A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50% or more while not affecting a corresponding TNF-α related activity level by more than comprises providing a pharmaceutical composition comprising a local anaesthetic, in particular lidocaine hydrochloride, and a pharmaceutically acceptable carrier, administering the composition intraperitoneally to said person, thereby substantially reducing the recruitment of macrophages by MCP-1 released from the endometriosis implant. Also disclosed is a corresponding pharmaceutical composition. | 05-09-2013 |
20130172422 | DESENSITIZING DRUG PRODUCT - Desensitizing drug products, methods of making desensitizing drug products, and methods of using desensitizing drug products including delivery of desensitizing drug products. In one embodiment, the desensitizing drug products are male genital desensitizers that comprise one or anesthetic agents and one or more melting point depressing agents. | 07-04-2013 |
20130184351 | LIDOCAINE PATCH AND METHODS OF USE THEREOF - This invention is directed to a transdermal delivery patch comprising local anesthetic agent and optionally a permeation enhancement agent for reducing neuropathic pain. | 07-18-2013 |
20130203856 | FILLER COMPOSITION FOR TISSUE REINFORCEMENT - The present invention relates to a filler composition for tissue reinforcement, including hyaluronic acid and alkylene diamine crosslinked hydrogel. The filler composition exhibits the positive physical properties required for tissue reinforcement, such as biocompatibility and swelling ability, as well as useful effects in that the same can remain in vivo for a long time. | 08-08-2013 |
20130210920 | DESENSITIZING DRUG PRODUCT - Desensitizing drug products, methods of making desensitizing drug products, and methods of using desensitizing drug products including delivery of desensitizing drug products. In one embodiment, the desensitizing drug products are male genital desensitizers that comprise one or anesthetic agents and one or more melting point depressing agents. | 08-15-2013 |
20130289124 | PHENYLCYCLOBUTYLAMIDE DERIVATIVES AND THEIR STEREOISOMERS, THE PREPARATION PROCESSES AND USES THEREOF - Phenylcyclobutylamide derivatives and their optical isomers, the preparing processes and the uses thereof, which includes the compounds of formula (I), their pure stereoisomers and their pharmaceutically acceptable salts. In formula (I), R is H, formacyl, acetyl, haloacetyl, benzoyl, benzyloxy carbonyl (Cbz), t-butoxy carbonyl (Boc), or 9-fluorenyl methoxyl carbonyl (Fmoc). The present novel compounds have pharmaceutical activity and are prepared by condensation reaction of racemic, levo- or dextro-demethyl Sibutramine and racemic or D/L isoleucine under a mild condition. It is demonstrated that the present compounds have effect of losing weight to obese mode rats in different level and the effect is better than Sibutramine by the animal experiments. So the medicaments prepared by the present compounds or the medicaments prepared by the compositions of the present compounds and other pharmaceutical activity compounds may be used for treating obesity. | 10-31-2013 |
20130303620 | Injectable Capsaicin - The present invention provides compositions and methods for relieving pain at a site in a human or animal in need thereof by administering at a discrete site in a human or animal in need thereof a dose of capsaicin in an amount effective to denervate a discrete site without eliciting an effect outside the discrete location, the dose of capsaicin ranging from 1 μg to 3000 μg. | 11-14-2013 |
20130317111 | DESENSITIZING DRUG PRODUCT - Desensitizing drug products, methods of making desensitizing drug products, and methods of using desensitizing drug products including delivery of desensitizing drug products. In one embodiment, the desensitizing drug products are male genital desensitizers that comprise one or anesthetic agents and one or more melting point depressing agents. | 11-28-2013 |
20130324611 | METHODS OF USING DESENSITIZING DRUG PRODUCTS - Desensitizing drug products, methods of making desensitizing drug products, and methods of using desensitizing drug products including delivery of desensitizing drug products. In one embodiment, the desensitizing drug products are male genital desensitizers that comprise one or anesthetic agents and one or more melting point depressing agents. | 12-05-2013 |
20130324612 | AQUEOUS GEL FORMULATION AND METHOD FOR INDUCING TOPICAL ANESTHESIA - Disclosed is a stable aqueous gel formulation suitable for topical use comprising water, an anesthetic (e.g., lidocaine hydrochloride), a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile and has low particulate count. Also disclosed is a method of inducing topical anesthesia on a tissue or organ, e.g., the eye, of an animal comprising providing a stable aqueous gel formulation comprising water, an anesthetic, a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile, and topically administering an effective amount of the aqueous gel formulation to the tissue or organ of the animal. | 12-05-2013 |
20140039061 | HYALURONIC ACID COMPOSITION - An injectable hyaluronic acid composition including a hyaluronic acid; a local anesthetic selected from the group of amide and ester type local anesthetics or a combination thereof; and an ascorbic acid derivative in an amount which prevents or reduces the effect on the viscosity and/or elastic modulus G′ of the composition caused by the local anesthetic upon sterilization by heat. Further, the medical and non-medical, such as cosmetic, use of such a composition, and a method of manufacturing such a composition. | 02-06-2014 |
20140039062 | INJECTABLE DEVICE AND METHOD FOR SCULPTING, AUGMENTING OR CORRECTING FACIAL FEATURES SUCH AS THE CHIN - An injectable device useful for facial sculpting and correction of facial features, for example, for augmenting the chin in a human being is provided, the device being made of a composition comprising a hyaluronic acid crosslinked with a multifunctional polyethylene glycol (PEG)-based crosslinking agent. | 02-06-2014 |
20140080913 | Sensory-Specific Local Anesthesia and Prolonged Duration Local Anesthesia - Combinations of charged local anesthetics with chemical permeation enhancers have been developed to give long duration block which is selective for sensory block is greatly prolonged by combining the local anesthetic with a permeation enhancer. The selectivity of sensory over motor block is provided by selecting the concentration of the local anesthetic and the permeation enhancer to provide selective permeability of the sensory and motor neurons to the enhancer. | 03-20-2014 |
20140142190 | BIODEGRADABLE SINGLE-PHASE COHESIVE HYDROGELS - Biodegradable single-phase cohesive hydrogels useful, e.g., for the formulation of viscosupplementation compositions or compositions for filling wrinkles, contain a homogeneous blend of x polymers, which may be identical or different, crosslinked prior to the interpenetration thereof by mixing in the form of a single-phase hydrogel, wherein such crosslinked polymers are insoluble in water and miscible with one another, and x ranges from 2 to 5; in one embodiment, the hydrogels are such that the x polymers have identical or different degrees of crosslinking, at least one of the x polymers having a degree of crosslinking x1 and at least one of the x polymers having a degree of crosslinking x2, with x1 being greater than or equal to x2. | 05-22-2014 |
20140142191 | PRODUCTION OF THERMOREVERSIBLE HYDROGELS FOR THERAPEUTIC APPLICATIONS - A method is disclosed for production of a sterile thermoreversible hydrogel characterized by a known temperature T | 05-22-2014 |
20140171509 | Non-Aqueous Patch - Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base. | 06-19-2014 |
20140194523 | DESENSITIZING DRUG PRODUCTS AND METHODS OF USE - Desensitizing drug products, methods of making desensitizing drug products, and methods of using desensitizing drug products including delivery of desensitizing drug products are disclosed herein. | 07-10-2014 |
20140235725 | PRECONFIGURED GEL WITH INFUSED DRUG FOR ULTRASOUND - Embodiments associated with an ultrasound conductive medium are described. In one embodiment, an ultrasound conductive medium is formed into a preconfigured shape, wherein the ultrasound conductive medium includes a composition combined with a drug. | 08-21-2014 |
20140288184 | GYLOXIME DERIVATIVE AND PEST CONTROL AGENT - The present invention provides a glyoxime derivative displaying excellent pesticidal effect or a salt thereof and a pesticide containing the same as an active ingredient. This pesticide is characterized by containing as an active ingredient, a glyoxime derivative expressed by the general formula [I] (in which X represents a cyano group or a carbamoyl group, R | 09-25-2014 |
20140323577 | METHODS FOR REDUCING THE RISK OF CONVERSION TO CLINICALLY DEFINITE MULTIPLE SCLEROSIS - This invention relates to a method for reducing the risk of conversion to clinically definite multiple sclerosis (CDMS) in patients who have experienced their first neurological symptoms consistent with clinically isolated syndrome (CIS). | 10-30-2014 |
20140323578 | POLYMERIC COLORANT COMPOSITIONS AND METHODS OF USE - A composition is disclosed. The composition comprises at least one polymeric colorant having a polymer component with a colorant component covalently bound thereto, a medicament, and a liquid vehicle. The at least one colorant component does not react directly or indirectly with the medicament. Methods of using the polymeric colorants, including a method for the preparation of skin as a site for a surgical procedure and a method of treating a medical condition, are also provided. | 10-30-2014 |
20140329906 | THERMOGELLING ANAESTHETIC COMPOSITIONS - The present invention relates to a thermogelling pharmaceutical composition comprising local anaesthetics in base form and which is suitable for topical administration. The compositions further comprise a polyoxyethylene castor oil and one or more surfactants to obtain thermogelling characteristics. | 11-06-2014 |
20140378549 | IMPLANTATION COMPOSITIONS FOR USE IN TISSUE AUGMENTATION - A composition of matter and method for preparation of a tissue augmentation material. A polysaccharide gel composition is prepared with rheological properties selected for a particular selected application. The method includes preparing a polymeric polysaccharide in a buffer to create a polymer solution or gel suspending properties in the gel and selecting a rheology profile for the desired tissue region. | 12-25-2014 |
20150011640 | GYNECOLOGIC COMPOSITION TO TREAT VULVAR VESTIBULITIS - A gynecologic composition contains spermidine to treat vulvar vestibulitis syndrome (VVS). In this therapeutic context, spermidine is effective at around one micromole per applied dose in the form of a simple salt or complex, alone or in combination or in conjunction with auxiliary actives such as anaesthetics and estrogens. | 01-08-2015 |
20150011641 | HIGH LOAD DISPERSIONS - The present invention relates to the field of carrier and delivery systems for active molecular compounds. In particular, the present invention provides aqueous dispersions for delivery of active molecular compounds. | 01-08-2015 |
20150025152 | FORMULATION AND METHOD OF USE OF A TREATMENT FOR SHINGLES PAIN - A pharmaceutical formulation for treatment of shingles is provided. The formulation includes between 0.2 mg of menthol per 120 mL of the formulation and 1.0 mg of menthol per 120 mL of the formulation, camphor water, lime water, and a local anesthetic. The local anesthetic includes one of between 0.6 mL of phenol per 120 mL of the formulation and 2.0 mL of phenol per 120 mL of the formulation and between 0.25% concentration by weight of lidocaine and 5% concentration by weight of lidocaine. | 01-22-2015 |
20150065577 | METHOD OF TREATING BINGE EATING DISORDER - The invention provides methods of treating binge eating disorders, obesity resulting from binge eating behavior, and depression. The invention includes methods of treating certain co-morbidities in ADHD and ADD patients; for example the invention includes methods of treating generalized anxiety disorder, obsessional and ruminative thought disorders, and obsessive/compulsive behavior in ADHD and ADD patients. The invention also includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered with one or more other active agents. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention. | 03-05-2015 |
20150087714 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS - The invention features a method for inhibiting one or more voltage-gated ion channels in a cell by contacting the cell with (i) a first compound that activates a channel-forming receptor that is present on nociceptors and/or pruriceptors; and (ii) a second compound that inhibits one or more voltage-gated ion channels when applied to the internal face of the channels but does not substantially inhibit said channels when applied to the external face of the channels, wherein the second compound is capable of entering nociceptors or pruriceptors through the channel-forming receptor when the receptor is activated. The invention also features a quaternary amine derivative or other permanently or transiently charged derivative of a compound that inhibits one or more voltage-gated ion channels when applied to the internal face of the channels but does not substantially inhibit said channels when applied to the external face of the channels. | 03-26-2015 |
20150119467 | METHODS FOR TREATMENT OF PELVIC PAIN AND/OR COMORBID CONDITIONS - Methods, systems, devices, and medicaments are provided for locally administering to a pelvic-area organ or tissue structure in a patient at least one drug continuously or continually over a treatment period of 24 hours or more in an amount effective to achieve a therapeutic effect in another organ or tissue structure by means of shared or convergent pelvic afferent pathways. The methods systems, devices, and medicaments can be used in the treatment of IC/BPS, chronic pelvic pain, vulvodynia, orchialgia, urethral syndrome, dysparenia, chronic prostatitis, chronic pelvic pain, levator ani syndrome, irritative bowel syndrome, or a combination thereof. The drug may include anesthetic agents, analgesic agents, antispasmodic agents, antimuscarinic agents, and combinations thereof. The drug may be released from a drug delivery device or a sustained release composition deployed inside the bladder. | 04-30-2015 |
20150297492 | DRY DERMAL FILLER COMPOSITIONS AND METHODS OF RECONSTITUTION - Dermal fillers are provided, particularly hyaluronic acid-based dermal fillers containing additives, for example, unstable additives, the dermal fillers being provided in an anhydrous state for extended shelf life. | 10-22-2015 |
20150374645 | DEVICES AND METHODS FOR SUSTAINED TREATMENT OF BLADDER PAIN AND IRRITATIVE VOIDING - Devices and methods are provided for treating a patient having bladder pain and/or irritative voiding symptoms. The method includes administering to the patient's bladder lidocaine or another anesthetic agent continuously over a treatment period of 24 hours or more in an amount effective to achieve a therapeutic effect which is sustained beyond the end of the treatment period. | 12-31-2015 |
20160074307 | THREADS OF HYALURONIC ACID AND/OR DERIVATIVES THEREOF, METHODS OF MAKING THEREOF AND USES THEREOF - The present invention provides threads of hyaluronic acid, and/or derivatives thereof, methods of making thereof and uses thereof, for example, in aesthetic applications (e.g., dermal fillers), surgery (sutures), drug delivery, etc. | 03-17-2016 |
20160089440 | POTENCY-EXTENDING AGENT OF BOTULINUM TOXIN TYPE-A PRODUCT - A potency-extending agent of a botulinum toxin type-A product includes 1 ml of distilled water, 85 of dextrose, 4.28 mg of sodium chloride, and 10 mg of trehalose. | 03-31-2016 |
20160136276 | DESENSITIZING DRUG PRODUCT - Desensitizing drug products, methods of making desensitizing drug products, and methods of using desensitizing drug products including delivery of desensitizing drug products. In one embodiment, the desensitizing drug products are male genital desensitizers that comprise one or anesthetic agents and one or more melting point depressing agents. | 05-19-2016 |
20160144043 | METHOD FOR CROSSLINKING HYALURONIC ACID; METHOD FOR PREPARING AN INJECTABLE HYDROGEL; HYDROGEL OBTAINED; USE OF THE OBTAINED HYDROGEL - The present invention relates to a method for crosslinking hyaluronic acid, a method for preparing an injectable hydrogel, the hydrogel thus obtained and its use. | 05-26-2016 |
20160184432 | Non-Aqueous Patch - Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base. | 06-30-2016 |
20160376618 | PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE AND RELATED DERIVATIVES - The present invention is directed to processes for the preparation of lisdexamfetamine and related derivatives, wherein the processes comprise coupling to racemic or enantiomerically enriched amphetamine and wherein the resulting product is advantageously enantiomerically or diastereomerically enriched in the desired stereoisomer. | 12-29-2016 |
20220133658 | TOPICAL ANALGESIC COMPOSITIONS AND METHODS OF USE - The present invention is directed to topical skin composition comprising one or more active ingredients and one or more permeation enhancers. The present invention is further directed to a method of reducing or eliminating pain. | 05-05-2022 |